Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) a leading RNAi therapeutics company today announced that management will present a company overview at the Cowen and Company 33rd Annual Health Care Conference on Tuesday March 5 2013 at 8:40 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the News & Investors section of the company’s website www.alnylam.com. A replay of the presentation will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR) ALN-AT3 for the treatment of hemophilia and rare bleeding disorders (RBD) ALN-AS1 for the treatment of acute intermittent porphyria ALN-PCS for the treatment of hypercholesterolemia and ALN-TMP for the treatment of hemoglobinopathies. As part of its “Alnylam 5x15TM” strategy the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development including programs in advanced stages on its own or with a partner by the end of 2015. Alnylam has additional partnered programs in clinical or development stages including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancers. The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck Medtronic Novartis Biogen Idec Roche Takeda Kyowa Hakko Kirin Cubist Ascletis Monsanto Genzyme and The Medicines Company. In addition Alnylam holds a significant equity position in Regulus Therapeutics Inc. a company focused on discovery development and commercialization of microRNA therapeutics. Alnylam has also formed Alnylam Biotherapeutics a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers including many in the world’s top scientific journals such as Nature Nature Medicine Nature Biotechnology and Cell. Founded in 2002 Alnylam maintains headquarters in Cambridge Massachusetts. For more information please visit www.alnylam.com.Business Wire
Last updated on: 27/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.